BioRestorative Therapies (BRTX) delays Q2 10-Q amid losses and going-concern risk
BioRestorative Therapies (BRTX) has filed a notification for late filing of its Q2 2026 Form 10-Q due to recent resignations of its CEO/Chairman and CFO, and disputes over employment agreements. The company anticipates reporting continued net losses, requiring additional capital, and has previously indicated โฆ